Etiology of perianal Crohn's disease: Role of genetic, microbiological, and immunological factors

Inflammatory Bowel Diseases

Volumn 15, Issue 10, 2009, Pages 1591-1598

  Tozer, Philip J ^a,b   Whelan, Kevin ^c   Phillips, Robin K S ^a,b   Hart, Ailsa L ^a,b  

^a ST MARK S HOSPITAL   (United Kingdom)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

^c KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Crohn's disease; Etiology; Immunology; Microbiology; Perianal fistula

Indexed keywords

ANTIBIOTIC AGENT; AZATHIOPRINE; CASPASE RECRUITMENT DOMAIN PROTEIN 15; CIPROFLOXACIN; DEFENSIN; GELATINASE B; IMMUNOGLOBULIN; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; MATRIX METALLOPROTEINASE; MERCAPTOPURINE; METRONIDAZOLE; ORGANIC CATION TRANSPORTER; PLACEBO; STROMELYSIN; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA;

ADAPTIVE IMMUNITY; AGE DISTRIBUTION; ANUS DISEASE; ANUS FISTULA; AUTOPHAGY; CHROMOSOME 5Q; CLINICAL TRIAL; CROHN DISEASE; DRUG EFFICACY; EPITHELIUM CELL; GENE LOCUS; GENETIC POLYMORPHISM; GENETIC PREDISPOSITION; GENETIC SUSCEPTIBILITY; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; HEREDITY; HUMAN; IDIOPATHIC FISTULA; IMMUNOPATHOLOGY; INFLAMMATION; LYMPHOCYTE MIGRATION; LYMPHOCYTE PROLIFERATION; LYMPHOCYTIC INFILTRATION; MESENCHYME CELL; MICROBIOLOGY; MICROFLORA; MYOFIBROBLAST; PATHOGENESIS; PRIORITY JOURNAL; RACE; RECURRENCE RISK; REVIEW; RISK FACTOR; SEX DETERMINATION; TREATMENT DURATION; TREATMENT RESPONSE;

ANUS DISEASES; CROHN DISEASE; HUMANS; IMMUNOLOGIC FACTORS;

EID: 70450175674     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1002/ibd.21026     Document Type: Review

References (75)

1. Penner A, Crohn BB. Perianal fistulae as a complication of regional ileitis. Ann Surg. 1938;108:867-873.
2. Ardizzone S, Porro GB. Perianal Crohn's disease: overview. Dig Liver Dis. 2007;39:957-958.
3. Schwartz DA, Loftus EV Jr, Tremaine WJ, et al. The natural history of fistulizing Crohn's disease in Olmsted County, Minnesota. Gastroenterology. 2002;122:875-880.
4. Tang LY, Rawsthorne P, Bernstein CN. Are perineal and luminal fistulas associated in Crohn's disease? A population-based study. Clin Gastroenterol Hepatol. 2006;4:1130-1134. (Pubitemid 44311656)
5. Gasche C, Scholmerich J, Brynskov J, et al. A simple classification of Crohn's disease: report of the Working Party for the World Congresses of Gastroenterology, Vienna 1998. Inflamm Bowel Dis. 2000;6:8-15.
6. Satsangi J, Silverberg MS, Vermeire S, et al. The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications. Gut. 2006;55:749-753. (Pubitemid 43764536)
7. Cosnes J, Cattan S, Blain A, et al. Long-term evolution of disease behavior of Crohn's disease. Inflamm Bowel Dis. 2002;8:244-250. (Pubitemid 34784976)
8. Hellers G, Bergstrand O, Ewerth S, et al. Occurrence and outcome after primary treatment of anal fistulae in Crohn's disease. Gut. 1980;21:525-527. (Pubitemid 10059414)
9. Beaugerie L, Seksik P, Nion-Larmurier I, et al. Predictors of Crohn's disease. Gastroenterology. 2006;130:650-656.
10. Lapidus A, Bernell O, Hellers G, et al. Clinical course of colorectal Crohn's disease: a 35-year follow-up study of 507 patients. Gastroenterology. 1998;114:1151-1160. (Pubitemid 28243900)
11. Tarrant KM, Barclay ML, Frampton CM, et al. Perianal disease predicts changes in Crohn's disease phenotype-results of a population-based study of inflammatory bowel disease phenotype. Am J Gastroenterol. 2008;103:3082-3093.
12. Bell SJ, Williams AB, Wiesel P, et al. The clinical course of fistulating Crohn's disease. Aliment Pharmacol Ther. 2003;17:1145-1151. (Pubitemid 36605751)
13. Karban A, Itay M, Davidovich O, et al. Risk factors for perianal Crohn's disease: the role of genotype, phenotype, and ethnicity. Am J Gastroenterol. 2007;102:1702-1708. (Pubitemid 47206693)
14. Russell RK, Ip B, Aldhous MC, et al. Anti-Saccharomyces cerevisiae antibodies status is associated with oral involvement and disease severity in Crohn disease. J Pediatr Gastroenterol Nutr. 2009;48:161-167.
15. Hughes LE. Surgical pathology and management of anorectal Crohn's disease. J R Soc Med. 1978;71:644-651.
16. Armuzzi A, Ahmad T, Ling KL, et al. Genotype-phenotype analysis of the Crohn's disease susceptibility haplotype on chromosome 5q31. Gut. 2003;52:1133-1139. (Pubitemid 36877425)
17. Onnie CM, Fisher SA, Prescott NJ, et al. Diverse effects of the CARD15 and IBD5 loci on clinical phenotype in 630 patients with Crohn's disease. Eur J Gastroenterol Hepatol. 2008;20:37-45.
18. Palmieri O, Latiano A, Valvano R, et al. Variants of OCTN1-2 cation transporter genes are associated with both Crohn's disease and ulcerative colitis. Aliment Pharmacol Ther. 2006;23:497-506. (Pubitemid 43382004)
19. Vermeire S, Pierik M, Hlavaty T, et al. Association of organic cation transporter risk haplotype with perianal penetrating Crohn's disease but not with susceptibility to IBD. Gastroenterology. 2005;129:1845-1853. (Pubitemid 41772963)
20. Roediger WE, Nance S. Metabolic induction of experimental ulcerative colitis by inhibition of fatty acid oxidation. Br J Exp Pathol. 1986;67:773-782. (Pubitemid 17212913)
21. Latiano A, Palmieri O, Cucchiara S, et al. Polymorphism of the IRGM gene might predispose to fistulizing behavior in Crohn's disease. Am J Gastroenterol. 2009;104:110-116.
22. Brant SR, Picco MF, Achkar JP, et al. Defining complex contributions of NOD2/CARD15 gene mutations, age at onset, and tobacco use on Crohn's disease phenotypes. Inflamm Bowel Dis. 2003;9:281-289.
23. Angelberger S, Reinisch W, Dejaco C, et al. NOD2/CARD15 gene variants are linked to failure of antibiotic treatment in perianal fistulating Crohn's disease. Am J Gastroenterol. 2008;103:1197-1202. (Pubitemid 351677965)
24. Brand S, Staudinger T, Schnitzler F, et al. The role of Toll-like receptor 4 Asp299Gly and Thr399Ile polymorphisms and CARD15/NOD2 mutations in the susceptibility and phenotype of Crohn's disease. Inflamm Bowel Dis. 2005;11:645-652. (Pubitemid 40965520)
25. Weersma RK, Stokkers PC, van Bodegraven AA, et al. Molecular prediction of disease risk and severity in a large Dutch Crohn's disease cohort. Gut. 2009;58:388-395.
26. Yamamoto T, Allan RN, Keighley MR. Effect of fecal diversion alone on perianal Crohn's disease. World J Surg. 2000;24:1258-1262. (Pubitemid 30803591)
27. Janowitz HD, Croen EC, Sachar DB. The role of the fecal stream in Crohn's disease: an historical and analytic review. Inflamm Bowel Dis. 1998;4:29-39. (Pubitemid 128699834)
28. Rutgeerts P, Goboes K, Peeters M, et al. Effect of faecal stream diversion on recurrence of Crohn's disease in the neoterminal ileum. Lancet. 1991;338:771-774.
29. Harper PH, Lee EC, Kettlewell MG, et al. Role of the faecal stream in the maintenance of Crohn's colitis. Gut. 1985;26:279-284. (Pubitemid 15054209)
30. Darfeuille-Michaud A, Neut C, Barnich N, et al. Presence of adherent Escherichia coli strains in ileal mucosa of patients with Crohn's disease. Gastroenterology. 1998;115:1405-1413. (Pubitemid 28545991)
31. Masseret E, Boudeau J, Colombel JF, et al. Genetically related Escherichia coli strains associated with Crohn's disease. Gut. 2001;48:320-325. (Pubitemid 32269558)
32. Chen W, Li D, Wilson I, et al. Detection of Chlamydia pneumoniae by polymerase chain reaction-enzyme immunoassay in intestinal mucosal biopsies from patients with inflammatory bowel disease and controls. J Gastroenterol Hepatol. 2002;17:987-993.
33. Huijsdens XW, Linskens RK, Taspinar H, et al. Listeria monocytogenes and inflammatory bowel disease: detection of Listeria species in intestinal mucosal biopsies by real-time PCR. Scand J Gastroenterol. 2003;38:332-333. (Pubitemid 36469996)
34. Naser SA, Ghobrial G, Romero C, et al. Culture of Mycobacterium avium subspecies paratuberculosis from the blood of patients with Crohn's disease. Lancet. 2004;364:1039-1044. (Pubitemid 39248662)
35. Romero C, Hamdi A, Valentine JF, et al. Evaluation of surgical tissue from patients with Crohn's disease for the presence of Mycobacterium avium subspecies paratuberculosis DNA by in situ hybridization and nested polymerase chain reaction. Inflamm Bowel Dis. 2005;11:116-125. (Pubitemid 40711215)
36. Hart AL, Stagg AJ, Frame M, et al. The role of the gut flora in health and disease, and its modification as therapy. Aliment Pharmacol Ther. 2002;16:1383-1393. (Pubitemid 34953580)
37. Ott SJ, Musfeldt M, Wenderoth DF, et al. Reduction in diversity of the colonic mucosa associated bacterial microflora in patients with active inflammatory bowel disease. Gut. 2004;53:685-693. (Pubitemid 38561447)
38. Sepehri S, Kotlowski R, Bernstein CN, et al. Microbial diversity of inflamed and noninflamed gut biopsy tissues in inflammatory bowel disease. Inflamm Bowel Dis. 2007;13:675-683. (Pubitemid 46909981)
39. Manichanh C, Rigottier-Gois L, Bonnaud E, et al. Reduced diversity of faecal microbiota in Crohn's disease revealed by a metagenomic approach. Gut. 2006;55:205-211. (Pubitemid 43117279)
40. Favier C, Neut C, Mizon C, et al. Fecal beta-D-galactosidase production and Bifidobacteria are decreased in Crohn's disease. Dig Dis Sci. 1997;42:817-822. (Pubitemid 27196036)
41. Swidsinski A, Ladhoff A, Pernthaler A, et al. Mucosal flora in inflammatory bowel disease. Gastroenterology. 2002;122:44-54. (Pubitemid 34049193)
42. Ott SJ, Plamondon S, Hart A, et al. Dynamics of the mucosa-associated flora in ulcerative colitis patients during remission and clinical relapse. J Clin Microbiol. 2008;46:3510-3513.
43. West RL, Van der Woude CJ, Endtz HP, et al. Perianal fistulas in Crohn's disease are predominantly colonized by skin flora: implications for antibiotic treatment? Dig Dis Sci. 2005;50:1260-1263.
44. Lunniss PJ, Faris B, Rees HC, et al. Histological and microbiological assessment of the role of microorganisms in chronic anal fistula. Br J Surg. 1993;80:1072. (Pubitemid 23261607)
45. Seow-Choen F, Hay AJ, Heard S, et al. Bacteriology of anal fistulae. Br J Surg. 1992;79:27-28.
46. De Hertogh G, Aerssens J, Geboes KP, et al. Evidence for the involvement of infectious agents in the pathogenesis of Crohn's disease. World J Gastroenterol. 2008;14:845-852. (Pubitemid 351325023)
47. Bernstein LH, Frank MS, Brandt LJ, et al. Healing of perineal Crohn's disease with metronidazole. Gastroenterology. 1980;79:599. (Pubitemid 10056413)
48. Brandt LJ, Bernstein LH, Boley SJ, et al. Metronidazole therapy for perineal Crohn's disease: a follow-up study. Gastroenterology. 1982;83:383-387.
49. Turunen U, Farkkila M, Seppala K. What is new and what is established in inflammatory bowel diseases: proceedings of the International Meeting on Inflammatory Bowel Diseases Athens, 19-23 April, 1989. Long-term treatment of peri-anal or fistulous Crohn's disease with ciprofloxacin. Scand J Gastroenterol. 1989;24:144.
50. Solomon M, McLeod R, O'Connor B, et al. Combination ciprofloxacin and metronidazole in severe perineal Crohn's disease. Can J Gastroenterol. 1993;571-573.
51. Bataille F, Klebl F, Rummele P, et al. Morphological characterisation of Crohn's disease fistulae. Gut. 2004;53:1314-1321. (Pubitemid 39120119)
52. Powell DW, Mifflin RC, Valentich JD, et al. Myofibroblasts. II. Intestinal subepithelial myofibroblasts. Am J Physiol. 1999;277:C183-C201.
53. Baugh MD, Perry MJ, Hollander AP, et al. Matrix metalloproteinase levels are elevated in inflammatory bowel disease. Gastroenterology. 1999;117:814-822. (Pubitemid 29468223)
54. Pender SL, MacDonald TT. Matrix metalloproteinases and the gut - new roles for old enzymes. Curr Opin Pharmacol. 2004;4:546-550.
55. Brenmoehl J, Falk W, Goke M, et al. Inflammation modulates fibronectin isoform expression in colonic lamina propria fibroblasts (CLPF). Int J Colorectal Dis. 2008;23:947-955.
56. Di SA, Pender SL, Jackson CL, et al. Functional modulation of Crohn's disease myofibroblasts by anti-tumor necrosis factor antibodies. Gastroenterology. 2007;133:137-149.
57. McKaig BC, Hughes K, Tighe PJ, et al. Differential expression of TGF-beta isoforms by normal and inflammatory bowel disease intestinal myofibroblasts. Am J Physiol Cell Physiol. 2002;282:C172-C182. (Pubitemid 34662564)
58. Kirkegaard T, Hansen A, Bruun E, et al. Expression and localisation of matrix metalloproteinases and their natural inhibitors in fistulae of patients with Crohn's disease. Gut. 2004;53:701-709. (Pubitemid 38561449)
59. Ascanelli S, de TD, Gregorio C, et al. Autologous fibroblasts transplant after infliximab administration: a new approach in Crohn's perianal fistulas? Brief clinical report. Int J Colorectal Dis. 2007;22:1135-1136. (Pubitemid 47500263)
60. Kiehne K, Fincke A, Brunke G, et al. Antimicrobial peptides in chronic anal fistula epithelium. Scand J Gastroenterol. 2007;42:1063-1069. (Pubitemid 47301134)
61. Gersemann M, Wehkamp J, Fellermann K, et al. Crohn's disease - defect in innate defence. World J Gastroenterol. 2008;14:5499-5503.
62. Bataille F, Rohrmeier C, Bates R, et al. Evidence for a role of epithelial mesenchymal transition during pathogenesis of fistulae in Crohn's disease. Inflamm Bowel Dis. 2008;14:1514-1527.
63. Pearson DC, May GR, Fick GH, et al. Azathioprine and 6-mercaptopurine in Crohn disease. A meta-analysis. Ann Intern Med. 1995;123:132-142.
64. Dejaco C, Harrer M, Waldhoer T, et al. Antibiotics and azathioprine for the treatment of perianal fistulas in Crohn's disease. Aliment Pharmacol Ther. 2003;18:1113-1120. (Pubitemid 38021597)
65. Present DH, Rutgeerts P, Targan S, et al. Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med. 1999;340:1398-1405. (Pubitemid 29205403)
66. Sands BE, Anderson FH, Bernstein CN, et al. Infliximab maintenance therapy for fistulizing Crohn's disease. N Engl J Med. 2004;350:876-885. (Pubitemid 38252535)
67. Asteria CR, Ficari F, Bagnoli S, et al. Treatment of perianal fistulas in Crohn's disease by local injection of antibody to TNF-alpha accounts for a favourable clinical response in selected cases: a pilot study. Scand J Gastroenterol. 2006;41:1064-1072. (Pubitemid 44385064)
68. Poggioli G, Laureti S, Pierangeli F, et al. Local injection of infliximab for the treatment of perianal Crohn's disease. Dis Colon Rectum. 2005;48:768-774. (Pubitemid 40880725)
69. Ruffolo C, Scarpa M, Faggian D, et al. Cytokine network in rectal mucosa in perianal Crohn's disease: relations with inflammatory parameters and need for surgery. Inflamm Bowel Dis. 2008;14:1406-1412.
70. Hlavaty T, Pierik M, Henckaerts L, et al. Polymorphisms in apoptosis genes predict response to infliximab therapy in luminal and fistulizing Crohn's disease. Aliment Pharmacol Ther. 2005;22:613-626. (Pubitemid 41415989)
71. van Assche G, Vanbeckevoort D, Bielen D, et al. Magnetic resonance imaging of the effects of infliximab on perianal fistulizing Crohn's disease. Am J Gastroenterol. 2003;98:332-339. (Pubitemid 36232382)
72. Parks AG. Pathogenesis and treatment of fistuila-in-ano. Br Med J. 1961;1:463-469.
73. McColl I. The comparative anatomy and pathology of anal glands. Arris and Gale lecture delivered at the Royal College of Surgeons of England on 25th February 1965. Ann R Coll Surg Engl. 1967;40:36-67.
74. Henrichsen S, Christiansen J. Incidence of fistula-in-ano complicating anorectal sepsis: a prospective study. Br J Surg. 1986;73:371-372. (Pubitemid 16112090)
75. Lunniss PJ, Sheffield JP, Talbot IC, et al. Persistence of idiopathic anal fistula may be related to epithelialization. Br J Surg. 1995;82:32-33.